If there’s one area of unmet medical need highlighting the challenges of oncology drug development, it’s pancreatic ductal adenocarcinoma (PDAC) and advanced disease in particular.

Bowling ’em over with quirky data, Guv!

Recently, several research groups have published papers showing the results of preclinical studies targeting KRAS mutations in pancreatic cancer.

Could the raft of novel KRASG12D inhibitors and degraders in development have a potential therapeutic role to play?

In our latest review, we discuss what actionnable insights for drug development can be taken from this recent research, as well as some of the challenges associated with translational research in this area given the limitations of preclinical models.

Do we need to think beyond KRAS and tackle the stroma first?  In this post we highlight some companies who are already looking into this approach.

Finally, we pull this together in the context of other oncogenes like MYC and discuss how it impacts the tumour microenvironment. Targeting PDAC is complex, but the pieces of the jigsaw are gradually being put together…

To continue reading our latest highlights on oncology new product development including commentary and analysis, BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by